X4 PHARMACEUTICALS, INC Prepaid Expense and Other Assets, Current
X4 PHARMACEUTICALS, INC (XFOR) had Prepaid Expense and Other Assets, Current of $3.34 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:PrepaidExpenseAndOtherAssetsCurrent · last filed 2026-08-06
- 2026-06-30: Prepaid Expense and Other Assets, Current $3.34M.
- 2026-03-31: Prepaid Expense and Other Assets, Current $2.51M.
- 2025-12-31: Prepaid Expense and Other Assets, Current $3.53M.
- 2025-09-30: Prepaid Expense and Other Assets, Current $4.92M.
| Period end | Prepaid Expense and Other Assets, Current | Prepaid Expense and Other Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $3.34M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $2.51M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $3.53M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $4.92M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $4.96M 10-Q · filed 2025-08-08 | |
| 2025-03-31 | $4.48M 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $5.59M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $4.48M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $4.98M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $5.76M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $7.30M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $5.80M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $5.52M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $4.16M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $5.81M 10-K · filed 2024-03-21 | |
| 2022-09-30 | $4.95M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $4.36M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $3.59M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $5.34M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $3.66M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $5.16M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $4.25M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $3.68M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $4.47M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $5.63M 10-Q · filed 2020-08-04 | |
| 2020-03-31 | $3.48M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $1.10M 10-K · filed 2021-03-19 | |
| 2019-09-30 | $1.23M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $1.60M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $2.37M 10-Q · filed 2019-05-15 | |
| 2018-12-31 | $1.21M 10-K · filed 2020-03-12 | $1.37M 10-K · filed 2019-03-11 |
| 2018-09-30 | $1.26M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $4.39M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $2.55M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $1.13M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |